Inventor · disambiguated record
Thomas Blankenstein
Also filed as: BLANKENSTEIN THOMAS
12 granted patents·9 pending applications·55 citations·filing 1995–2023
86Inventor score
Files withMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT8MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN MDC BERLIN BUCH3MAX DELBRUECK CENTRUM2BLANKENSTEIN THOMAS1CHARO JEHAD1
Top patents by PatentIndex Score
21 records- 0190US8486694B2Generation of antigen specific T cellsSCHENDEL DOLORES·Filed 2006·Granted Jul 16, 2013·20 cites·17 claims
- 0281US9133264B2Epitope-tag surface expressed proteins and nucleic acids thereofBLANKENSTEIN THOMAS·Filed 2007·Granted Sep 15, 2015·13 cites·12 claims
- 0373US12338272B2High avidity antigen recognizing constructsMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN MDC BERLIN BUCH·Filed 2022·Granted Jun 24, 2025·0 cites·2 claims
- 0473US10377808B2High avidity antigen recognizing constructsMAX DELBRUECK CENTRUM FUER MOLEDULARE MEDIZIN MDC BERLIN BUCH·Filed 2014·Granted Aug 13, 2019·5 cites·8 claims
- 0565US11447536B2High avidity antigen recognizing constructsMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN MDC BERLIN BUCH·Filed 2019·Granted Sep 20, 2022·0 cites·21 claims
- 0659US6039941ALive vaccine for the treatment of tumor diseasesMAX DELBRUECK CENTRUM·Filed 1995·Granted Mar 21, 2000·17 cites·17 claims
- 0757US2025098651A1A non-human mammal comprising in its genome at least two human leukocyte antigen (hla) class i alleles, methods of making such mammal and uses thereofMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT·Filed 2023·Application pending·0 cites
- 0854US2024189352A1T-cell receptors specific for both rac1- and rac2-derived mutated epitopesMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT·Filed 2022·Application pending·0 cites
- 0950US2025101078A1Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kitT KNIFE GMBH·Filed 2023·Application pending·0 cites
- 1048US2014141026A1Generation of antigen specific t cellsHELMHOLTZ ZENTRUM MUENCHEN·Filed 2013·Application pending·0 cites
- 1144US2008201791A1T Cell Line-Based Packaging Cell Line for the Production of Retroviruses by Enriching of Cd3 Expressing CellsUCKERT WOLFGANG·Filed 2006·Application pending·0 cites
- 1243US12421290B2CD22-specific T cell receptors and adoptive T cell therapy for treatment of B cell malignanciesMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT·Filed 2019·Granted Sep 23, 2025·0 cites·23 claims
- 1342US12479903B2CD5 specific T cell receptor cell or gene therapyMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT·Filed 2020·Granted Nov 25, 2025·0 cites·21 claims
- 1442US10683336B2Tumor specific T-cell receptorsMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN MDC BERLIN BUCH·Filed 2013·Granted Jun 16, 2020·0 cites·4 claims
- 1541US10781243B2Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT·Filed 2016·Granted Sep 22, 2020·0 cites·43 claims
- 1641US2019359677A1Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseasesMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT·Filed 2018·Application pending·0 cites
- 1740US9061058B2Use of Pol III promoters for controlled expression of therapeutic proteinsCHARO JEHAD·Filed 2007·Granted Jun 23, 2015·0 cites·8 claims
- 1838US2011189141A1Multiple target t cell receptorMAX DELBRUECK CENTRUM·Filed 2010·Application pending·0 cites
- 1938US2021061876A1T cell receptors for tumor specific proteasome splice variants and uses thereofMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT·Filed 2019·Application pending·0 cites
- 2037US11401316B2High avidity HPV T-cell receptorsMAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN HELMHOLTZ GEMEINSCHAFT·Filed 2016·Granted Aug 2, 2022·0 cites·19 claims
- 2133US2016222080A1Multiple target t cell receptorMax-Delbrück-Centrum für Molekulare Medizin ·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →